Sanyo Co., Ltd. Overview
Sanyo is a family-built Japanese specialist that has made almost nothing but swabs for more than half a century, a focus captured in its motto "綿棒一筋" (single-minded about swabs). It reports about 40% of Japan's general-use swab market by value, a position its parent describes as top class. It designs its own production lines and makes its own paper shafts through a group company. Its industrial HUBY swabs, sold by subsidiary Clean Cross, serve semiconductor, electronics, optical, hard-disk and other precision production. Medical, specimen-collection and nursing-care swabs form a third line, supported by ISO 13485 certification and a dedicated plant opened in 2024. Output comes from Osaka and Vietnam, and exports were about 30% of sales in 2023. Group revenue is only JPY 3.6 billion, but the balance sheet is exceptionally liquid. Under Mitsui Matsushima, the task is to turn a cash-rich niche maker into a faster-growing supplier of high-value consumables.
The company profiled is Sanyo Co., Ltd. (株式会社山洋) of Tondabayashi, Osaka, Japan, website www.sa-n-yo.co.jp. It makes cotton swabs and cotton balls, and its HUBY brand of industrial swabs is used in cleanrooms and precision manufacturing. It is unrelated to Sanyo Denki (TSE: 6516), the former Sanyo Electric, and the resin and textile trader 株式会社三洋.
Sanyo has been a wholly owned, unlisted subsidiary of Mitsui Matsushima Holdings Co., Ltd. (TSE Prime and Fukuoka: 1518) since 21 August 2026.
Sanyo describes its business simply as the manufacture and sale of cotton swabs and cotton balls. Its website presents it as a dedicated maker of safe, high-quality Japanese swabs for general, industrial and medical use, and it also takes novelty and original-product orders. In a 2025 Osaka Prefecture interview, the company called itself one of Japan's few specialist makers covering household, industrial and medical swabs. Its working slogan, "たかが綿棒、されど綿棒", means roughly "only a swab, yet still a swab".
The independent characterization is a vertically integrated niche consumables group with three economic engines:
General-use swabs: high-volume, low-priced consumer goods sold through drugstores, supermarkets, home centers and e-commerce. They supply scale, brand recognition and factory absorption.
Industrial swabs: low-lint, low-residue HUBY products that command a much higher unit price. They reach users through Clean Cross, the sole general distributor, and through catalog and laboratory resellers.
Medical and care swabs: regulated products sold to clinics, hospitals and nursing settings, including sterile items and specimen collection swabs.
The model is almost entirely product revenue. Subscription and licensing income are not reported. Sanyo also does OEM and novelty work, and it sells licensed SNOOPY-branded swabs as a licensee.
Raw material: Sanyo's position: Purchases absorbent cotton, pulp and plastics
Shafts: Sanyo's position: Paper shafts made by group company Santec
Machinery: Sanyo's position: Develops its own production lines; first swab machine built in 1969
Manufacturing: Sanyo's position: Tondabayashi head plant, Medical Plant and Sanyo Vietnam
Quality: Sanyo's position: In-house inspection, ISO 9001 and ISO 13485 systems
Distribution: Sanyo's position: Sales agents and wholesalers, retailers, Clean Cross, e-commerce, overseas resellers
End users: Sanyo's position: Households, fabs and electronics plants, optics and auto makers, clinics, care facilities
End markets span personal care, baby care, cosmetics, nursing care, ENT and gynecology clinics, diagnostic specimen collection, semiconductors, electronic components, optics, hard disks, liquid-crystal displays and automobiles. A 2023 feature named computer, smartphone and car makers as HUBY users.
Strategy
Sanyo's stated direction has three elements: strengthening its "commitment to manufacturing" and high quality, building competitiveness against foreign rivals, and aiming for the top share in high-value markets. President Hibi's message identifies low birth rates, an aging population, rapid growth among Chinese companies and M&A among Western firms as the main pressures.
The parent's thesis adds resources. Mitsui Matsushima plans to bring cost management and productivity know-how, expand capital expenditure, strengthen supply and support overseas sales. Its stated aim is to accelerate industrial and medical growth and improve profitability. It cites data-center investment and semiconductor demand as the key drivers for industrial swabs.
Mitsui Matsushima integration: Date: Aug 2026; Target or scope: Cost, productivity, capex, overseas support; Status: Under way
Industrial growth: Date: 2026 onward; Target or scope: Semiconductor, electronics and optical demand; Status: Announced; capex not publicly disclosed
US supply: Date: Before Jul 2026; Target or scope: Supply to the largest US swab seller; Status: Begun; customer not named
Asia premium expansion: Date: To 2027; Target or scope: Double-digit share growth in Asian countries; Status: Long-standing goal
Medical Plant: Date: 2024; Target or scope: Medical device and related manufacturing; Status: Operating
Nursing and oral care: Date: Apr 2026; Target or scope: PureMORE gauze sticks that replicate finger-wrapped gauze care; Status: Launched
Ear-care products: Date: Sep 2025–Jun 2026; Target or scope: mimiuru lotion swab for summer ear care; Status: Launched and promoted
Value paper packaging: Date: Apr 2026; Target or scope: Antibacterial swabs in 500-count paper box; Status: Launched
Sanyo has no standalone financial targets. The relevant target belongs to the parent: net income of at least JPY 10 billion by FY March 2030, supported by about JPY 40 billion of investment across M&A, listed-equity investing and group-company growth. The parent also targets a payout of about 40% by that year and has adopted progressive dividends.
Products & Services
Industrial: HUBY
| Model | Description | Key specification | Typical use |
|---|---|---|---|
| BB-001 | Three-inch baby swab | Paper shaft; 100 and 5,000 pack formats | Fine cleaning |
| BB-002 | Fine baby swab, slim type | Paper shaft; 100 and 6,250 pack formats | Narrow gaps |
| BB-003 | Micro swab, sharp point slim | 79 mm long, 3.0 mm tip, double-ended, pulp shaft | Microscopes, optics, connectors, precision processes |
| BB-012 | Fine baby swab 2.0 | Paper shaft; 8,000 pack format | Fine detail |
| BB-013 | Hard sharp point slim swab | Paper shaft; 8,000 pack format | Precise pressure cleaning |
| CA-002 | Round double-ended swab | Long-staple cotton shaped on both ends | Cleanroom cleaning |
| CA-003 | Cotton applicator | 2,500 pack format | General cleaning and application |
| CA-005 | Cotton applicator | 100 and 6,000 pack formats | General cleaning and application |
| CA-006 | Six-inch applicator | 148 mm, wooden shaft, single rounded head | Scrubbing with solvent |
| CA-007 | Cotton applicator | 100 and 2,000 pack formats | General cleaning and application |
| CA-008 | Cotton applicator | 100 and 1,600 pack formats | General cleaning and application |
| CA-010 | Motor assay applicator | 50 and 2,100 pack formats | Motor assembly cleaning |
| FS-010 | Flat swipe | 0.5 × 3.8 mm tip, conductive plastic shaft | Static-sensitive work |
| HUBY APEX | Premium line launched 2007 | Detailed specification held by Clean Cross | Precision applications |
HUBY takes its name from "huge probability". It launched in 1990 and is sold as HUBY-340. Sanyo says the range holds a global share among high-tech business swabs and is used in China, Thailand, the Philippines, Taiwan, South Korea, the United States and Europe. Clean Cross holds the detailed specifications.
The range is built on six stated attributes: strong water absorption, cotton that does not swell, low non-volatile residue, lintless finishing, silicone-free packaging and easy incineration. Residue data for purified water, isopropyl alcohol and acetone are available on request. RoHS2 non-use certificates can be issued for HUBY, but not for general-use swabs.
Reference retail pricing shows the economics. BB-003 sells at about JPY 647 for 100 pieces through Kaunet, or about JPY 6.5 each. Kodawari 180-count sells at JPY 168 through Tsuruha, or about JPY 0.9 each. Industrial swabs therefore carry roughly seven times the unit price of a mainstream consumer swab at retail. Manufacturer selling prices are not publicly disclosed.
Medical
| Product | Description | Specification | Launch or status |
|---|---|---|---|
| HUBY-COTIX 604-A-1 | Six-inch pure swab | Wooden shaft, binder-free 100% cotton, individual pack | HUBY-COTIX line launched 1997 |
| HUBY-COTIX 610-S-1 | Six-inch pure soft swab | 9.5 mm cotton head, wooden shaft, individual pack | Current |
| HUBY-COTIX EN3-50S | 3 mm medical assistance swab | Reinforced plastic shaft, bendable, 50 count | Current |
| HUBY-COTIX EN4-50M | 4 mm medical assistance swab | Reinforced plastic shaft, bendable, 50 count | Current |
| HUBY-COTIX specimen swab | Nasopharyngeal and nasal collection | Polyester tip, polystyrene shaft, electron-beam sterilized, Class I | Launched July 2021 |
| Dr. HUBY micro | 3 mm laparoscopic surgical swab | Developed with Osaka University | Launched 2017; discontinued March 2025 |
The specimen swab has no fixed break point, so users can snap it to suit different tubes. Its filing number is 27B3X00067000025. Sanyo's launch materials reported a 90% concordance with a competing flocked swab in PCR comparison testing.
General use
| Series | Positioning | Flagship items |
|---|---|---|
| Kodawari | Premium Japanese swab with anti-loss neck, rounded shaft tip and 10% stronger paper shaft | 180 count, 150 count, 110 count, 50 count wrapped |
| 至福 360° | Ear-pick feel across the full head | 100 count; black 100 and 50 count |
| 綿棒カルテ | Individually wrapped, problem-based range launched 2025 | Sticky, ear-pick, wet and daily swabs |
| Black swabs | Dark tip makes debris visible | Black adhesive 20 count; black 360° 100 count |
| Sanyo Vietnam products | Value antibacterial paper-shaft swabs | 200 count, 180 refill, ring type, 500 paper box |
| HOSSO | Slim swab for adults | 200 count; black version added September 2026 |
| スゴふわっ | Very soft, large head | 110 count |
| mimiuru | Ear lotion swab with seven botanical ingredients | Launched September 2025 |
| Osaka dialect fortune swab | Gift and souvenir novelty | 110 count |
| SNOOPY | Licensed antibacterial swabs | SN 200 count, PN 110 count |
| Baby | Animal-themed thin swabs | Hamu 280, Usa 250, Kuma 180, Koala 200 |
| nico | Makeup swabs | Soft 100, Hard 130, Flat & Make 30 |
| Nursing care | Sterile swabs and oral care | Sterile 30 and 15 count; PureMORE gauze sticks |
Cotton balls and services
Sanyo sells cotton balls and a 500 g lintless cotton ball for medical use. It also offers novelty and OEM production for corporate customers, and it sells through its own online promotional store. Consumer prices are set by retailers, and contract pricing is not publicly disclosed.
Financial Narrative
Mitsui Matsushima's 22 July 2026 filing and published deal summaries provide three years of unaudited, simplified consolidated data. Results for FY2022 and FY2023, gross profit, EBITDA, cash flow statements and debt details are not publicly disclosed.
Income statement
Revenue fell 8.9% in FY2025 and rose 8.4% in FY2026, leaving it 1.3% below FY2024. The two-year revenue CAGR is -0.7%. Operating income rose 85.4% in FY2026 and net income rose 91.5%. The swing shows meaningful operating leverage on a small revenue base, as about JPY 282 million of added revenue produced JPY 181 million of added operating income. Company-level explanations for the swing are not publicly disclosed.
Non-operating income is unusually important. It was JPY 226 million in FY2026, equal to 58% of operating income. Its composition is not publicly disclosed, but the large cash balance and foreign operations make financial income and foreign exchange plausible contributors. Ordinary income therefore overstates the earnings power of the swab business, and operating income is the better measure of the assets Mitsui Matsushima bought.
Balance sheet
Net cash at February 2026 was about JPY 6.5 billion, equal to about 65% of total assets and 72% of net assets. Liabilities were JPY 971 million, so debt can be no more than that amount. The short and long-term debt split, goodwill, intangibles and working capital are not publicly disclosed.
Equity changes do not fully track earnings less dividends. Net income minus dividends implies a rise of about JPY 205 million in FY2025 and JPY 399 million in FY2026, compared with actual rises of JPY 306 million and JPY 276 million. The reconciling items are not publicly disclosed.
Ratios
ROE of about 4.5% reflects excess capital more than weak operations. Dividends of about JPY 7.5 million a year show that the former owners kept almost all earnings inside the company. Removing about JPY 6.5 billion of net cash from equity leaves about JPY 2.6 billion of operating capital. On that base, FY2026 operating income represents a pre-tax return of about 15%. This arithmetic is indicative, because the mix of non-cash assets and liabilities is undisclosed.
Sanyo has no material net debt, so net debt to EBITDA and interest coverage are not meaningful. ROIC, the current ratio and the cash conversion cycle cannot be calculated from public figures. The November 2026 consolidation may show an initial asset-and-goodwill picture at parent level, although Sanyo-specific balances may remain undisclosed.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Revenue by Segment and Segment Margins & Growth (%)
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Group revenue (JPY Mn) | 3,689 | 3,359 | 3,641 |
Group operating income (JPY Mn) | 337 | 212 | 393 |
Group operating margin (%) | 9.1 | 6.3 | 10.8 |
Group revenue growth (%) | — | -8.9 | 8.4 |
Business Lines
| Business line | Contents | Principal route to market |
|---|---|---|
General use | Hygiene, baby, makeup and nursing-care swabs | Drugstores, supermarkets, home centers, e-commerce |
Medical | HUBY-COTIX medical assistance and specimen swabs | Medical wholesalers and agents |
Industrial | HUBY cleaning swabs | Clean Cross and industrial resellers |
Cotton balls | Cotton balls and lintless cotton balls | Medical and hygiene channels |
OEM and novelty | Promotional and original swab products | Direct corporate sales |
Group company | Established | Capital |
Sanyo Co., Ltd. | 1,980 | JPY 60 million |
Sanyo Vietnam Co., Ltd. | Apr 2008 | USD 600,000 |
Clean Cross Co., Ltd. | Apr 2005 | JPY 9 million |
Santec Inc. | Oct 1984 | JPY 50 million |
Income Statement and Per-Share Data
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Revenue (JPY Mn) | 3,689 | 3,359 | 3,641 |
Operating income (JPY Mn) | 337 | 212 | 393 |
Non-operating income, net (JPY Mn) | 182 | 143 | 226 |
Ordinary income (JPY Mn) | 519 | 355 | 619 |
Net income (JPY Mn) | 375 | 212 | 406 |
EPS (JPY) | 2,508 | 1,417 | 2,715 |
Dividend per share (JPY) | 50 | 50 | 50 |
Operating margin (%) | 9.1 | 6.3 | 10.8 |
Ordinary margin (%) | 14.1 | 10.6 | 17.0 |
Net margin (%) | 10.2 | 6.3 | 11.2 |
Balance Sheet and Per-Share Data
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Total assets (JPY Mn) | 9,150 | 9,574 | 10,049 |
Net assets (JPY Mn) | 8,496 | 8,802 | 9,078 |
Total liabilities (JPY Mn) | 654 | 772 | 971 |
Book value per share (JPY) | 56,823 | 58,869 | 60,715 |
Equity ratio (%) | 92.9 | 91.9 | 90.3 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
ROE on year-end equity (%) | 4.4 | 2.4 | 4.5 |
ROA on year-end assets (%) | 4.1 | 2.2 | 4.0 |
Asset turnover (times) | 0.40 | 0.35 | 0.36 |
Dividend payout (%) | 2.0 | 3.5 | 1.8 |
Liabilities to net assets (times) | 0.08 | 0.09 | 0.11 |
Region Overview
| Region | Share of sales | Commentary |
|---|---|---|
Japan | About 70% (2023 statement) | Mature, with strong general-use share and a growing medical presence |
Exports | About 30% (2023 statement) | HUBY and premium consumer swabs; country split not publicly disclosed |
Parent Market Measure Details
| Parent market measure | Value |
|---|---|
Share price, 2 Nov 2026 (JPY) | 2,246 |
Close before announcement, 22 Jul 2026 (JPY) | 1,553 |
Change since announcement (%) | 44.6 |
1-year change, 2 Nov 2026 (%) | 73.2 |
52-week high, 27 Jul 2026 (JPY) | 2,403 |
52-week low, 5 Nov 2025 (JPY) | 1,245 |
P/E on company forecast (times) | 9.8 |
P/B (times) | 1.44 |
Forecast dividend yield (%) | 5.8 |
Per-Share Data and Income Statement
| Parent metric | FY2025 | FY2026 | FY2027F |
|---|---|---|---|
Dividend per share (JPY) | 26 | 64 | 130 |
Net income (JPY Mn) | — | 6,716 | 8,600 |
Revenue (JPY Mn) | — | 65,468 | 71,000 |
Operating income (JPY Mn) | — | 9,573 | 10,000 |
Analyst Conclusions
No Sanyo-specific guidance or consensus exists. Parent guidance for FY3/2027 calls for sales of JPY 71 billion, operating income of JPY 10 billion, ordinary income of JPY 10.4 billion and net income of JPY 8.6 billion. The July revision added JPY 3 billion to sales and JPY 300 million to operating income, partly because of Sanyo. Sanyo's exact contribution was not separated.
HUBY becomes a true semiconductor consumables franchise: Evidence: Parent cites data-center and chip demand; pricing is far above consumer swabs
Parent improves weak returns: Evidence: Operating capital earns well, but group ROE is held down by cash; productivity programs can lift margin
New volume channels diversify growth: Evidence: Largest US swab seller, Asian premium demand and nursing-care launches
Bear case: Evidence: Evidence
The semiconductor story is larger than the actual sales base: Evidence: HUBY sales are undisclosed; total revenue is below USD 25 million at JPY 150
Margin expansion proves difficult: Evidence: FY2025 operating margin was only 6.3%, and consumer swabs are price-sensitive
Integration disrupts know-how: Evidence: Chairman exited, six new directors arrived, and process skill is central
Key catalysts (next 12 months):
13 Nov 2026: Catalyst: Parent first-half results; What to monitor: Goodwill, segment placement and first Sanyo commentary
19 Nov 2026: Catalyst: Osaka Healthcare Business Contest final; What to monitor: External validation of healthcare plan
By May 2027: Catalyst: Parent FY3/2027 results; What to monitor: Actual Sanyo contribution and capex
During 2027: Catalyst: Sanyo's 60th anniversary; What to monitor: Progress on Asian share target
2027: Catalyst: Vietnam and Tondabayashi investment; What to monitor: Capacity, automation and supply decisions
Ongoing: Catalyst: US supply; What to monitor: Scale, customer disclosure and margin
Ongoing: Catalyst: Semiconductor capex cycle; What to monitor: HUBY order trends
Analyst verdict. Sanyo is best understood as a high-quality niche manufacturer that was bought mainly for its operating optionality and strong balance sheet. It is not a pure semiconductor company. Its label in the semiconductor ecosystem is justified by HUBY's real use in precision cleaning, but public evidence does not show how much of the group's JPY 3.6 billion revenue comes from that market. Consumer swabs still appear to provide much of the group's scale.
Mitsui Matsushima's purchase looks disciplined. The headline price of JPY 9.4 billion is close to book value, while about JPY 6.5 billion of net cash reduces the implied price of the operations to about JPY 2.9 billion. At about seven times FY2026 operating income, the parent paid a reasonable price for a business with a strong domestic position, integrated supply, regulated capabilities and a respected industrial brand. The acquisition also removes the main historic drag: a founder-era capital structure that left too much money idle.
The investment case now turns on execution. Sanyo must prove that FY2026's recovery is durable, that HUBY can scale beyond its existing niche, and that US, Asian and nursing-care initiatives can raise revenue without sacrificing quality. The largest risks are overestimating the semiconductor exposure and damaging the process knowledge that makes the product special. Disclosure will remain limited, so outsiders should judge progress through parent-level commentary, capex and any named customer wins.
Overall, Sanyo is a credible, financially resilient consumables franchise with moderate rather than explosive prospects. Its next leg of value creation depends less on market growth than on management converting cash, brand and process expertise into higher operating profit under new ownership. The first useful evidence should arrive with Mitsui Matsushima's results on 13 November 2026.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Position | Appointed | Background |
|---|---|---|---|
Tsutomu Hibi (日比 努) | Representative Director and President | President since 2018 | Former vice president; also represents Clean Cross |
髙橋 宏樹 | Director | 21 Aug 2026 | Prior roles not publicly disclosed |
河端 康 | Director | 21 Aug 2026 | Prior roles not publicly disclosed |
Taishi Yoshioka (吉岡 泰士) | Director | 21 Aug 2026 | Representative Director and President of Mitsui Matsushima Holdings |
Mikiko Abe (阿部 美紀子) | Director | 21 Aug 2026 | Director and senior executive officer, corporate planning, at the parent |
呉本 竜介 | Director | 21 Aug 2026 | Prior roles not publicly disclosed |
日置 真路 | Director | 21 Aug 2026 | Prior roles not publicly disclosed |
野元 敏博 | Corporate Auditor | 21 Aug 2026 | Long-serving parent finance executive and later audit-committee director |
Major Shareholders
| Holder | Shares | Stake | Filing date |
|---|---|---|---|
Mitsui Matsushima Holdings Co., Ltd. | 149,516 | 100.0% | Extraordinary report, 22 Jul 2026; closed 21 Aug 2026 |
Competitive Landscape
Key Competitors
| Competitor | Arena | Ownership | Relative positioning |
|---|---|---|---|
Heiwa Medic | Consumer, medical, specimen | Private | Closest Japanese rival; plants in Takayama, China and Vietnam; strong inbound presence |
Hakujuji | Consumer and medical | Private | Broad Japanese hygiene and medical brand |
Nippon Menbo | Consumer | Private | Domestic swab specialist |
Pip | Consumer | Private | Household health-care brand |
Texwipe (ITW) | Cleanroom | Part of NYSE: ITW | Polyester and foam swabs; strong global contamination-control channel |
Chemtronics (ITW) | Electronics cleaning | Part of NYSE: ITW | Electronics cleaning and swab range |
Contec | Cleanroom | Private | Global cleanroom wipes and swabs |
Berkshire | Cleanroom | Private | Cleanroom consumables, including swabs |
Foamtec International WCC | Cleanroom | Private | Foam swab specialist |
Puritan Medical Products | Medical and controlled environments | Family-owned | Major specimen swab maker; also a past HUBY distributor |
Tanimura | Cleanroom Japan | Private | Japanese anti-static and clean swabs |
Q-tips | Consumer global | Unilever brand | Global consumer leader |
Jieyang Top-Tip's | Consumer global | Private | Named among leading global producers |
Groupe Lemoine | Consumer and medical | Private | European swab and cotton specialist |
Benchmark | Revenue (FY) | Growth | Operating margin |
Sanyo group | JPY 3.6 billion (FY2/2026) | 8.4% | 10.8% |
Mitsui Matsushima Holdings | JPY 65.5 billion (FY3/2026) | — | 14.6% |
ITW, total | USD 16,044 million (FY2025) | 0.9% | 26.3% |
ITW, Test & Measurement and Electronics | USD 2,825 million (FY2025) | 0.2% | 24.6% |
“—” = not publicly disclosed.
Recent Developments
Sanyo's September notice calls the event a "business transfer", but Mitsui Matsushima's filings describe a purchase of all issued shares.
